Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Crinetics Pharmaceuticals
(NASDAQ:CRNX)
Intraday
$45.05
0
[0.00%]
After-Hours
$45.05
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$45.05
0
[0.00%]
At close: May 1
$45.05
0
[0.00%]
PreMarket: 4:20PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Crinetics Pharmaceuticals Stock (NASDAQ:CRNX)
Crinetics Pharmaceuticals Stock (NASDAQ: CRNX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, April 03, 2024
Live On CNBC, StemPoint Capital CIO Michelle Ross Mentions Crinetics Pharmaceuticals As A GLP-1 Adjacent Play During Halftime Segment 'Opportunities In Biotech' Calling It Her "Best Biotech Idea"
Benzinga Newsdesk
-
Apr 3, 2024, 12:40PM
Thursday, March 28, 2024
JMP Securities Reiterates Market Outperform on Crinetics Pharmaceuticals, Maintains $80 Price Target
Benzinga Newsdesk
-
Mar 28, 2024, 10:41AM
Wednesday, March 20, 2024
Oppenheimer Maintains Outperform on Crinetics Pharmaceuticals, Raises Price Target to $55
Benzinga Newsdesk
-
Mar 20, 2024, 11:52AM
JMP Securities Maintains Market Outperform on Crinetics Pharmaceuticals, Raises Price Target to $80
Benzinga Newsdesk
-
Mar 20, 2024, 9:35AM
HC Wainwright & Co. Maintains Buy on Crinetics Pharmaceuticals, Raises Price Target to $60
Benzinga Newsdesk
-
Mar 20, 2024, 6:35AM
JonesTrading Maintains Buy on Crinetics Pharmaceuticals, Raises Price Target to $56
Benzinga Newsdesk
-
Mar 20, 2024, 6:08AM
Tuesday, March 19, 2024
Crinetics Pharmaceuticals shares are trading lower after the company filed for the resale of up to 8.33 million shares by the selling stockholders.
Benzinga Newsdesk
-
Mar 19, 2024, 4:46PM
Crinetics Pharmaceuticals Inc Files For Resale Of Up To 8.33M Shares By The Selling Stockholders
Benzinga Newsdesk
-
Mar 19, 2024, 4:43PM
Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why
Vandana Singh
-
Mar 19, 2024, 2:48PM
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Avi Kapoor
-
Mar 19, 2024, 1:48PM
HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $50 Price Target
Benzinga Newsdesk
-
Mar 19, 2024, 12:24PM
National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday
Avi Kapoor
-
Mar 19, 2024, 10:03AM
Market-Moving News for March 19th
Benzinga Newsdesk
-
Mar 19, 2024, 8:41AM
Crinetics Pharmaceuticals shares are trading higher after the company's Phase 3 PATHFNDR-2 trial of paltusotine in acromegaly achieved the primary and all secondary endpoints.
Benzinga Newsdesk
-
Mar 19, 2024, 6:19AM
Crinetics Pharmaceuticals Announced Topline Results From PATHFNDR-2 Phase 3 Trial Of Paltusotine For Acromegaly Achieving The Primary And All Secondary Endpoints; NDA Submission To FDA Expected In 2H 2024
Benzinga Newsdesk
-
Mar 19, 2024, 6:06AM
Wednesday, March 13, 2024
JMP Securities Reiterates Market Outperform on Crinetics Pharmaceuticals, Maintains $60 Price Target
Benzinga Newsdesk
-
Mar 13, 2024, 11:25AM
Oppenheimer Reiterates Outperform on Crinetics Pharmaceuticals, Raises Price Target to $54
Benzinga Newsdesk
-
Mar 13, 2024, 8:34AM
HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $50 Price Target
Benzinga Newsdesk
-
Mar 13, 2024, 7:29AM
Tuesday, March 12, 2024
Crinetics Announces Positive Topline Results From Phase 2 Trial Of Paltusotine For The Treatment Of Carcinoid Syndrome; Demonstrated Rapid And Sustained Reductions In Frequency And Severity Of Flushing Episodes And Bowel Movements
Benzinga Newsdesk
-
Mar 12, 2024, 4:26PM
Friday, March 08, 2024
HC Wainwright & Co. Maintains Buy on Crinetics Pharmaceuticals, Raises Price Target to $50
Benzinga Newsdesk
-
Mar 8, 2024, 6:36AM
Wednesday, March 06, 2024
Citigroup Initiates Coverage On Crinetics Pharmaceuticals with Buy Rating, Announces Price Target of $68
Benzinga Newsdesk
-
Mar 6, 2024, 5:19AM
Monday, March 04, 2024
Cantor Fitzgerald Maintains Overweight on Crinetics Pharmaceuticals, Raises Price Target to $65
Benzinga Newsdesk
-
Mar 4, 2024, 10:29AM
Friday, March 01, 2024
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
Avi Kapoor
-
Mar 1, 2024, 11:18AM
Thursday, February 29, 2024
JMP Securities Maintains Market Outperform on Crinetics Pharmaceuticals, Raises Price Target to $60
Benzinga Newsdesk
-
Feb 29, 2024, 2:19PM
Oppenheimer Maintains Outperform on Crinetics Pharmaceuticals, Raises Price Target to $48
Benzinga Newsdesk
-
Feb 29, 2024, 10:39AM
The Analyst Verdict: Crinetics Pharmaceuticals In The Eyes Of 6 Experts
Benzinga Insights
-
Feb 29, 2024, 8:01AM
Baird Maintains Outperform on Crinetics Pharmaceuticals, Raises Price Target to $52
Benzinga Newsdesk
-
Feb 29, 2024, 7:05AM
Wednesday, February 28, 2024
Crinetics Pharmaceuticals Q4 EPS $(0.90) Misses $(0.86) Estimate
Benzinga Newsdesk
-
Feb 28, 2024, 4:35PM
Crinetics Pharmaceuticals: Q4 Earnings Insights
Benzinga Insights
-
Feb 28, 2024, 4:35PM
Crinetics Pharmaceuticals shares are trading higher after the company announced an oversubscribed $350 million private placement.
Benzinga Newsdesk
-
Feb 28, 2024, 8:57AM
Crinetics Pharmaceuticals Announces Oversubscribed $350M Private Placement Of 8,333,334 Shares Of Common Stock At A Price Of $42/Share
Benzinga Newsdesk
-
Feb 28, 2024, 8:02AM
Earnings Scheduled For February 28, 2024
Benzinga Insights
-
Feb 28, 2024, 6:24AM
Tuesday, February 27, 2024
Crinetics Pharmaceuticals Earnings Preview
Benzinga Insights
-
Feb 27, 2024, 12:01PM
Friday, February 02, 2024
Cantor Fitzgerald Reiterates Overweight on Crinetics Pharmaceuticals, Maintains $50 Price Target
Benzinga Newsdesk
-
Feb 2, 2024, 9:52AM
Tuesday, January 23, 2024
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
-
Jan 23, 2024, 12:35PM
Tuesday, January 16, 2024
Morgan Stanley Initiates Coverage On Crinetics Pharmaceuticals with Overweight Rating, Announces Price Target of $50
Benzinga Newsdesk
-
Jan 16, 2024, 3:18PM
Wednesday, January 03, 2024
Radionetics Oncology Appoints Paul Grayson As The Chief Executive Officer
Benzinga Newsdesk
-
Jan 3, 2024, 7:20AM
Radionetics Oncology Raises $52.5M Series A To Advance First-in-Class Radiopharmaceutical Pipeline
Benzinga Newsdesk
-
Jan 3, 2024, 7:19AM
Thursday, December 28, 2023
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
-
Dec 28, 2023, 8:06AM
Tuesday, December 19, 2023
Endocrine Diseases-Focused Crinetics Pharmaceuticals Highlights Favorable Initial Findings From Mid-Stage Study
Vandana Singh
-
Dec 19, 2023, 12:51PM
Cantor Fitzgerald Reiterates Overweight on Crinetics Pharmaceuticals, Maintains $50 Price Target
Benzinga Newsdesk
-
Dec 19, 2023, 12:08PM
Crinetics Pharmaceuticals shares are trading higher after the company announced initial findings from its ongoing open-label Phase 2 study of paltusotine for the treatment of acromegaly and carcinoid syndrome.
Benzinga Newsdesk
-
Dec 19, 2023, 10:58AM
Analyst Scoreboard: 4 Ratings For Crinetics Pharmaceuticals
Benzinga Insights
-
Dec 19, 2023, 8:00AM
HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $42 Price Target
Benzinga Newsdesk
-
Dec 19, 2023, 7:43AM
Monday, December 18, 2023
Crinetics Announces Initial Findings From Ongoing Open-Label Phase 2 Study Of Paltusotine For The Treatment Of Carcinoid Syndrome
Benzinga Newsdesk
-
Dec 18, 2023, 4:06PM
Monday, December 04, 2023
Cantor Fitzgerald Reiterates Overweight on Crinetics Pharmaceuticals, Maintains $50 Price Target
Benzinga Newsdesk
-
Dec 4, 2023, 9:02AM
Monday, November 20, 2023
8 Analysts Have This to Say About Crinetics Pharmaceuticals
Benzinga Insights
-
Nov 20, 2023, 10:00AM
JP Morgan Reinstates Overweight on Crinetics Pharmaceuticals, Announces $35 Price Target
Benzinga Newsdesk
-
Nov 20, 2023, 8:12AM
Tuesday, November 14, 2023
President & CEO at Crinetics Pharmaceuticals Exercises Options Worth $1.41M
Benzinga Insights
-
Nov 14, 2023, 10:00AM
Tuesday, November 07, 2023
Crinetics Pharmaceuticals Q3 EPS $(1.01) Misses $(0.91) Estimate, Sales $346.00K Beat $120.00K Estimate
Benzinga Newsdesk
-
Nov 7, 2023, 5:21PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch